Results 171 to 180 of about 357,421 (301)

Advances in immunotherapy for renal cell carcinoma: a comprehensive review. [PDF]

open access: yesFront Immunol
Rajih E   +3 more
europepmc   +1 more source

Spontaneous Regression of Clear Cell Renal Cell Carcinoma Metastases or Immune Restoration? [PDF]

open access: yesCurr Oncol
Vacheret C   +5 more
europepmc   +1 more source

Surgical intervention for renal cell carcinoma with inferior vena cava extension combined with laparoscopic procedure

open access: yes, 2017
Toshio Kamimura,1 Kazutaka Kida,1 Masashi Takeda,1 Shunsuke Sato,1 Masato Fujii,1 Masahiro Inoue,1 Hiromasa Tsukino,1 Shoichiro Mukai,1 Atsushi Nanashima,2 Kunihide Nakamura,2 Toshiyuki Kamoto1 1Department of Urology, Faculty of Medicine, University of ...
Kamoto T   +10 more
core  

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Role of everolimus in the treatment of renal cell carcinoma

open access: yes, 2009
Saby George1, Ronald M Bukowski21University of Texas Health Sciences Center, MC-8221, Division of Hematology and Oncology, San Antonio, Texas, USA; 2CCF Lerner College of Medicine Division of Hematology and Oncology, Cleveland, Ohio, USAAbstract: The ...
Saby George, Ronald M Bukowski
core  

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher   +7 more
wiley   +1 more source

Prognostic Significance of NOTCH1-ICD Expression in Renal Cell Carcinoma. [PDF]

open access: yesJ Kidney Cancer VHL
Višić M   +7 more
europepmc   +1 more source

Interaction between cellular retinoic acid-binding protein II and histone hypoacetylation in renal cell carcinoma

open access: yes, 2008
Renal cell carcinoma is a rare but serious malignancy. Since a reduction in the level of retinoic acid receptor beta 2 (RARbeta2) expression in cancer cells due in part to histone hypoacetylation which is controlled by histone deacetylase (HD), the study
Viroj Wiwanitkit, Wiwanitkit, Viroj
core  

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong   +6 more
wiley   +1 more source

Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report. [PDF]

open access: yesIJU Case Rep
Nakamura K   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy